Delcath Systems, Inc. (NASDAQ:DCTH) Sees Large Decrease in Short Interest

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 15th total of 1,350,000 shares. Based on an average trading volume of 386,900 shares, the short-interest ratio is currently 2.7 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. purchased a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $808,000. Renaissance Technologies LLC acquired a new position in Delcath Systems in the second quarter valued at $694,000. Geode Capital Management LLC grew its holdings in shares of Delcath Systems by 3.0% during the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company's stock worth $2,275,000 after purchasing an additional 7,298 shares during the last quarter. Barclays PLC acquired a new stake in shares of Delcath Systems during the third quarter worth about $104,000. Finally, Polar Asset Management Partners Inc. purchased a new stake in shares of Delcath Systems in the 3rd quarter valued at about $1,594,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Price Performance

Shares of NASDAQ DCTH traded up $1.34 during midday trading on Thursday, hitting $14.05. The company's stock had a trading volume of 568,492 shares, compared to its average volume of 453,369. Delcath Systems has a 1 year low of $3.70 and a 1 year high of $14.04. The firm has a market capitalization of $449.15 million, a price-to-earnings ratio of -10.41 and a beta of 0.87. The business's fifty day simple moving average is $11.36 and its two-hundred day simple moving average is $9.85.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DCTH shares. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of Delcath Systems in a research report on Tuesday. Stephens reissued a "buy" rating on shares of Delcath Systems in a research note on Friday, October 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. Finally, StockNews.com upgraded shares of Delcath Systems from a "sell" rating to a "hold" rating in a report on Friday, October 25th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.